NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









iXCells Biotechnologies

iXCells Biotechnologies

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://ixcellsbiotech.com/

Last Round

Growth Equity

Sep 29, 2022

Company Overview

iXCells Biotechnologies is a biotechnology company that provides preclinical drug discovery solutions with a focus on disease-relevant cellular models, enabling technologies, and services to the academic, biotech, and pharma communities.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Biotech Equipment

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales

AI Layer

Application

Keywords

induced pluripotent stem cellsiPSCcontract research organizationCROprimary cellsCRISPR gene editingassay developmentdrug discovery servicesdisease modelingcell culture mediawet lab servicespreclinical researchcustom cell engineeringbiotech reagents

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

iXCells Biotechnologies Comparables

Compare iXCells Biotechnologies with similar companies based on industry and business-model similarity.

iXCells Biotechnologies comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Axol Bioscience
88%
Allele Biotechnology and Pharmaceuticals, Inc.
81%
BrainXell
81%

iXCells Biotechnologies Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Growth EquitySep 29, 2022

Key People

Founding team and executive leadership

Helge Bastian

Chief Executive Officer

Executive Team

iXCells Biotechnologies Investors

Notable investors and investment history

iXCells Biotechnologies investors
InvestorRounds
Great Point PartnersGrowth Equity

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 19, 2026

    Monthly visitors increased 57% MoM.

  • Nov 14, 2025

    Grew 19% QoQ, from 36 to 43 employees.

iXCells Biotechnologies Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

iXCells Biotechnologies Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about iXCells Biotechnologies's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range45
Year Founded2014
Last FundingSep 29, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.